Argent Biopharma Ltd · ASX:RGT
Argent Biopharma — MGC Pharmaceuticals — Investor Presentation (November 2015)
13 slides from Argent Biopharma's investor presentation, November 2015
Slide 1: MGC Pharmaceuticals
MGC Pharmaceuticals November 2015
Slide 2: Company Overview
Company Overview MGC Pharmaceuticals (MGC), is a medical and cosmetic cannabis company with licenses to grow, extract and sell Cannabis Sativa in Slovenia, inside MGC Pharmaceuticals the EU. Capitalising on “Israeli Medical Cannabis IP” – world leaders in the production and delivery of MGC holds uni
Slide 3: MGC Pharma - Key Points Of Difference
MGC Pharma- Key Points Of Difference • Positioned in the rapidly growing medical cannabis market (worth US$2.7bn globally) and cosmetic market (estimated at US$270bn globally in 2014) • Focused strategy to enter the Australian market following the favourable regulatory shift by the Federal Governmen
Slide 4: MC Industry Leaders - Expertise and Experience
MC Industry Leaders- Expertise and Experience Nativ Segev Roby Zomer Dr. Ross Walker Co-Founder and Brett Mitchell Co-Founder, President & Non-Executive Director and Managing Director Executive Chairman CTO Head of Advisory Board Joins upon completion of Previously CEO of Israel’s Wealth of industri
Slide 5: Business Model
Business Model MGC has a business model which closes the supply chain – demand exists for the end products and MGC is now working towards establishing the supply of the raw material. • Development of Cannabis Strains in Slovenian Laboratory Cultivation • Plantation and harvesting of crops in outdoor
Slide 6: Medical Cannabis could be legally available in Australia as early as 2016
Medical Cannabis could be legally available in Australia as early as 2016 6
Slide 7: MGC Australian Strategy
MGC Australian Strategy MGC to be first in line to exploit scalable commercial opportunities in Australia for CBD based expertise and products Appointment of Dr. Ross Walker as Non-Executive Director and Head of Strategic Advisory Board. Complete Collaboration with University of Sydney Business Scho
Slide 8: Global Market Opportunity – Medical Cannabis
Global Market Opportunity – Medical Cannabis • Cannabinoids are legal in 23 U.S states and the medical cannabis market is estimated to be worth USD$2.7 billion globally in 2014 and US$10 billion by 2019 • In Canada the market for medical cannabis is expected to grow significantly, from $144m in 2014
Slide 9: Cannabidiol (CBD) – Global Potential
Cannabidiol (CBD) – Global Potential Scientific and clinical studies indicate that CBD could be effective in easing symptoms of a wide range of difficult-to-control conditions, including: Tumors and Multiple Nausea Anxiety and Cancerous Sclerosis Depression Cells1 Inflammatory Rheumatoid Disorders S
Slide 10: Capital Structure
Capital Structure Ordinary Performance Unlisted Cash Shares Shares Options Current issued capital 507,586,552 Nil 53,500,000 $2.0m Shares to be issued to consultants 3,846,700 Nil Nil Nil and prospectus shares Underwriting Options to be issued Nil Nil 20,000,000 Nil MGC vendor consideration 200,000,
Slide 11: 2015 Weekly Share Price Movement
2015 Weekly Share Price Movement Share price movement 30 day moving average 60 day moving average 11
Slide 12: Disclaimer
Disclaimer This presentation has been prepared by Erin Resources Limited to be renamed MGC Pharmaceuticals Ltd (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the
Slide 13: Contact Information
Contact Information Media Enquiries Asher Moses Director Media and Capital Partners +61 438 008 616 Asher.moses@mcpartners.com.au ERI soon to be MGC Pharmaceuticals Brett Mitchell Executive Chairman +61 8 9389 2000 info@mgcpharma.com.au 13
MGC Pharmaceuticals — Investor Presentation (November 2015) on 6ix